The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) is a huge mover today! The stock decreased 4.44% or $1.21 during the last trading session, hitting $26.05. About 263,567 shares traded hands. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 120.02% since March 1, 2016 and is uptrending. It has outperformed by 107.80% the S&P500.
The move comes after 9 months negative chart setup for the $1.38 billion company. It was reported on Oct, 4 by Barchart.com. We have $23.97 PT which if reached, will make NASDAQ:AXDX worth $110.40 million less.
Analysts await Accelerate Diagnostics Inc (NASDAQ:AXDX) to report earnings on November, 7. They expect $-0.33 earnings per share, down 32.00% or $0.08 from last year’s $-0.25 per share. After $-0.35 actual earnings per share reported by Accelerate Diagnostics Inc for the previous quarter, Wall Street now forecasts -5.71% EPS growth.
Accelerate Diagnostics Inc (NASDAQ:AXDX) Ratings Coverage
Out of 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Accelerate Diagnostics has been the topic of 5 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, December 16 by Piper Jaffray. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9. William Blair initiated the shares of AXDX in a report on Friday, January 8 with “Outperform” rating. BTIG Research upgraded the shares of AXDX in a report on Tuesday, August 25 to “Neutral” rating. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) has “Overweight” rating given on Thursday, March 24 by JP Morgan.
According to Zacks Investment Research, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado.”
Insitutional Activity: The institutional sentiment decreased to 1.14 in Q2 2016. Its down 0.64, from 1.78 in 2016Q1. The ratio worsened, as 8 funds sold all Accelerate Diagnostics Inc shares owned while 28 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 12.54 million shares or 1.89% less from 12.78 million shares in 2016Q1.
Synovus has 0% invested in the company for 1,636 shares. Morgan Stanley accumulated 51,767 shares or 0% of the stock. Rhumbline Advisers has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). New York State Common Retirement Fund accumulated 24,200 shares or 0% of the stock. Selkirk Lc owns 291,400 shares or 2.53% of their US portfolio. Deutsche Bank Ag has 67,284 shares for 0% of their US portfolio. Albion Group Ut accumulated 70,543 shares or 0.18% of the stock. Parametric Associate Ltd Liability Corporation accumulated 0% or 21,026 shares. Nuveen Asset Lc holds 0.06% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 710,571 shares. Hightower Advsr Ltd Liability Corporation last reported 13,062 shares in the company. The Japan-based Blackrock Japan Ltd has invested 0% in Accelerate Diagnostics Inc (NASDAQ:AXDX). First Manhattan Co last reported 0% of its portfolio in the stock. Neuberger Berman Group Ltd Liability Corporation holds 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 48,000 shares. Schwab Charles Inv Mngmt Incorporated has 0% invested in the company for 98,416 shares. National Bank Of New York Mellon Corp has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX).
Insider Transactions: Since May 13, 2016, the stock had 9 buys, and 0 insider sales for $4.95 million net activity. Another trade for 15,967 shares valued at $218,748 was made by SCHULER JACK W on Monday, June 13.
More important recent Accelerate Diagnostics Inc (NASDAQ:AXDX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on February 28, 2013, also Benzinga.com published article titled: “Cramer Likes Accelerate Diagnostics Inc”, Seekingalpha.com published: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q2 2016 Results …” on August 08, 2016. More interesting news about Accelerate Diagnostics Inc (NASDAQ:AXDX) was released by: Globenewswire.com and their article: “Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno …” with publication date: July 11, 2016.
AXDX Company Profile
Accelerate Diagnostics, Inc., incorporated on December 24, 2012, is an in vitro diagnostics firm engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Firm is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.